| Literature DB >> 34047699 |
Sigal Shaklai1,2,3, Ran Gilad-Bachrach4,5, Elad Yom-Tov6,7, Naftali Stern1,2,3.
Abstract
BACKGROUND: Cerebrovascular disease is a leading cause of mortality and disability. Common risk assessment tools for stroke are based on the Framingham equation, which relies on traditional cardiovascular risk factors to predict an acute event in the near decade. However, no tools are currently available to predict a near/impending stroke, which might alert patients at risk to seek immediate preventive action (eg, anticoagulants for atrial fibrillation, control of hypertension).Entities:
Keywords: algorithm; archive; diagnosis; infodemiology; internet; prospective; risk; screening; search engines; stroke; trend
Year: 2021 PMID: 34047699 PMCID: PMC8196360 DOI: 10.2196/27084
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Number of users in the control cohorts according to various conditions and the search terms used to identify the group.
| Cohort | Terms or criteria used for identification | Users, N |
| 60-64 years old | According to information provided at registration to Bing | 108 |
| 65-74 years old | According to information provided at registration to Bing | 82 |
| >75 years old | According to information provided at registration to Bing | 38 |
| Depression | depression, depressed, ssri, citalopram, celexa, escitalopram, lexapro, fluoxetine, prozac, fluvoxamine, luvox, paroxetine, paxil, sertraline, zoloft, atomoxetine, Strattera, pristiq, desvenlafaxine, cymbalta, duloxetine, levomilnacipran, fetzima, milnacipran, ixel, savella, dalcipran, toledomin, sibutramine, meridia, tramadol, ultram, venlafaxine, effexor | 85 |
| Migraine | migraine, metoprolol, Lopressor, valproate, Depakote, epilim, topiramate, Topamax | 66 |
| B12 deficiency | B12 | 48 |
| Heart attack | heart attack, acute myocardial infarction | 101 |
| Hypothyroidism | hypothyroidism, levothyroxine, levoxyl, synthroid, tirosint, unithroid | 59 |
| Surgery | Prostatectomy, hip replacement, surgery | 369 |
| Atrial fibrillation | atrial fibrillation, anticoagulants, eliquis, apixaban, xarelto, rivaroxaban, pradaxa, dabigatran, lixiana, edoxaban, coumadin, warfarin, antiarrythmic, amiodarone, procor, cordarone, sotalol, flecainide, tambocor, propafenone, rythmol, dronedarone, multaq, dofetilide, tikosyn | 86 |
| Hypertension | hypertension, angiotensin receptor blocker, irbesartan, telmisartan, candesartan, atacand, valsartan, diovan, losartan, cozaar, losardex, olmesartan, benicar, ace inhibitor, benazepril, lotensin, captopril, cilazapril, enalapril, enaladex, fosinopril, lisinopril, ramipril, moexipril, cardiotensin, perindopril, quinapril, accupril, trandolapril, mavik, mineralocorticoid receptor antagonists, spironolactone, aldactone, carospir, eplerenone, inspra, diuretics, chlorthalidone, calcium channel blocker, amlodipine, norvasc, katerzia, diltiazem, cardizem, matzim, taztia, tiazac, verapamil, verap, alpha blocker, doxazosin, cardura, cadex | 78 |
| Alzheimer disease | ((I or my) AND (forgetting, misplacing, can't find, forget name)) OR Alzheimer OR dementia | 75 |
Figure 1Receiver operating characteristic curve for distinguishing users who underwent stroke from controls for people of different ages.
Figure 2Area under the receiver operating characteristic curve (AUC, left) and the true positive rate at a 1% false-positive rate for separating the patient cohort from each of the control cohorts.
Figure 3Receiver operating characteristic curve for the prospective cohort; the area under the curve (AUC) values for the different settings are presented in the legend.
Figure 4Area under the receiver operating characteristic curve (AUC) as a function of N_2, the number of days ahead for which the prediction is made. Different curves show different values of N_1, the time prior to stroke that is taken as nonstroke dates.
Figure 5Average classifier scores as a function of the time to estimated stroke date (left) and the number of times that each user had classifier scores greater than 0.95 (right) in the period between 120 days prior to the estimated stroke date and the day before.